Clinical trials
Large B-cell Lymphoma clinical trials
Below are recruiting large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07057765Recruiting
Blood markers for predicting DLBCL treatment response
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
Cairo, Cairo GovernorateAges 18–65 - NCT07059650RecruitingPhase 1/Phase 2
DZD8586 combo therapy for diffuse large B-cell lymphoma
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
BeijingAges 18 years+ - NCT07062627RecruitingPhase 2
CAR-T cell therapy for CNS lymphoma
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
SeoulAges 19 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07072208Recruiting
A Study of Four Drugs for Older Adults with DLBCL
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Suzhou, JiangsuAges 70 years+ - NCT07077512RecruitingPhase 2
CAR-T cells plus immunotherapy for advanced B-cell lymphoma
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
GuangzhouAges 18–70 - NCT07078500RecruitingPhase 2
Orelabrutinib plus Pola-R-CHP for untreated non-GCB DLBCL
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hangzhou, ZhejiangAges 18–80 - NCT07084662RecruitingPhase 2/Phase 3
Xinlikang capsule for fatigue after lymphoma treatment
This trial tests a Chinese herbal capsule, Xinlikang, to see if it helps reduce fatigue and improve immune function after chemotherapy for diffuse large B-cell lymphoma. It is for people who have finished their first treatment and still feel very tired.
Guangzhou, GuangdongAges 18 years+ - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07098364RecruitingPhase 1/Phase 2
ST-067 with CAR T-cell therapy for large B-cell lymphoma
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT07124936RecruitingPhase 1/Phase 2
Study of new drug plus standard care for large B-cell lymphoma
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Zaragoza, AragonAges 18 years+ - NCT07188077Recruiting
Study of immune changes in brain lymphoma
This trial looks at the immune system and metabolism of people with primary central nervous system lymphoma (a type of brain cancer) to find differences that might help with future treatments. It does not test a new drug, but collects samples and medical information.
Fuzhou, FujianAges 18–75 - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07198230Recruiting
DEB-TACE therapy for large lymphoma tumors that have returned or not responded
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
Fuzhou, FujianAges 18–75 - NCT07211048Recruiting
Gene therapy for B-cell lymphoma that hasn't responded to standard treatment
This trial tests a new gene therapy that re-engineers your own immune cells to attack CD19-positive lymphoma. It is for people whose B-cell lymphoma has come back or not responded to at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Scottsdale, ArizonaAges 18 years+ - NCT07249905RecruitingPhase 1/Phase 2
Testing MDX2003 for people with relapsed B-cell lymphoma
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
Richmond, VictoriaAges 18 years+ - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+ - NCT07260812RecruitingPhase 1
KSV01 injection for relapsed DLBCL
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
Wuhan, HubeiAges 18–65 - NCT07270263Recruiting
Lower-dose blood thinners for people with blood cancers
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for large b-cell lymphoma?
- Yes. Clin2 currently lists 393 recruiting large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.